In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biomet, Inc.

http://www.biomet.com/

Latest From Biomet, Inc.

Point Of Care Diagnostics Market Projected To Continue Rapid Growth

A new report from Informa's Meddevicetracker highlights strong projected growth in the market, explaining the underlying reasons why.

Market Intelligence In Vitro Diagnostics

Antios Raises $96m To Advance HBV Drug With Pharmasset Pedigree

Antios thinks ATI-2173, which employs the Pharmasset liver-targeting chemistry used in HCV blockbuster Sovaldi, can help produce a functional cure in hepatitis B combination therapy.

Financing Business Strategies

Abbott, BD, Quidel OTC COVID-19 Tests Granted Emergency Use Authorization In US

FDA grants emergency use authorization to OTC COVID-19 testing products as it targets allowing workplaces, schools and communities to access tools needed to screen for the virus rapidly and accurately.

Coronavirus COVID-19 FDA

FDA Grants Emergency Use Authorization To Variety Of OTC COVID-19 Tests

The US agency has granted emergency use authorization to consumer COVID-19 testing products from Quidel, Abbott and BD.

Coronavirus COVID-19 In Vitro Diagnostics
See All

Company Information

  • Other Names / Subsidiaries
    • Biomet Biologics, Inc.
UsernamePublicRestriction

Register